US FDA MFU Developments: 2024-2026 Clearances and Indications

I write about Ultherapy from a patient's seat, and that seat happens to be a Bay Area one — which means I track the FDA 510(k) database the way some of my friends track their cycling Strava. The 2024-2026 window has been busier than I expected on the U.S. side: a couple of meaningful Ulthera clearance updates, the Sofwave indication expansion, a slow-moving conversation about pediatric and contraindication language, and a competitive 510(k) trickle from smaller manufacturers. None of it changes my decision to keep flying to Seoul for the actual sessions, but it does change the consultation I have when I'm back home. Here's the reporter's read on what landed, what it means, and how the U.S. picture sits next to what I see on the Gangnam menu.

What the FDA 510(k) pathway actually does for an MFU device

The U.S. Food and Drug Administration's 510(k) pathway is the substantial-equivalence clearance route most aesthetic energy devices, including microfocused ultrasound platforms, use to reach the U.S. market — which means the manufacturer demonstrates that a new device or indication is meaningfully equivalent to a legally marketed predicate, rather than running the more demanding Premarket Approval gauntlet. For Ulthera and Sofwave, that pathway has shaped the rhythm of indication expansion since the original Ulthera clearance in 2009 and the Sofwave clearance in 2019.

What I want patients to understand, before I get into the 2024-2026 specifics, is that a 510(k) clearance is not the same as a clinical-superiority statement. It is a regulatory finding that the device is safe and substantially equivalent for a specified indication. The published outcome data, the operator's case volume, and the manufacturer's post-market surveillance record do additional work that the clearance letter does not. A 510(k) clearance is a permission slip, not a verdict.

A second point worth flagging. The FDA 510(k) database is publicly searchable, and any patient willing to spend ten minutes can verify a device's clearance history, the predicate device cited, and the cleared indication language. I link the database in the outbound section below. Marketing copy occasionally outpaces what the clearance letter actually permits, and the gap between the brochure and the database is the kind of detail that occasionally matters when you're sitting across from a U.S. provider explaining what was done in Korea.

Ulthera clearance updates in the 2024-2026 window

Ulthera, Inc. — the Merz Aesthetics subsidiary that holds the U.S. Ultherapy clearance record — filed and received clearance for the Prime hardware platform in early 2023, which I covered separately in the Korea launch update. The 2024-2026 window has been quieter on the headline-clearance side and more about indication-language refinement and post-market surveillance reporting. The cleared indications set has stayed largely consistent: brow lift, lifting of lax submental and neck tissue, and improvement of fine lines and wrinkles on the décolletage. What has shifted is how Merz markets the multi-cycle and combined-zone application of those indications, which the FDA has clarified through guidance language rather than new 510(k) numbers.

For patients, the practical effect of the 2024-2026 Ulthera updates has been twofold. First, the Prime platform's U.S. cartridge availability and per-zone pricing has stabilized after the initial 2023 launch period, which has meaningful downstream effects on how U.S. providers talk about pricing — and on the U.S.-versus-Korea cost comparison I find myself running every trip. Second, the multi-cycle conversation has matured: more U.S. providers are now structured to discuss Ulthera as a regimen across a two-to-three-year horizon rather than a single-session purchase, which mirrors how thoughtful Gangnam coordinators have been framing it for a while.

A caveat. The FDA does not, as a general rule, clear the multi-cycle protocol itself; it clears the device for the indication. The protocol is operator practice and emerging consensus rather than regulatory mandate. Patients comparing what a U.S. provider proposes to what a Korean provider proposes will find the cleared indication language identical and the protocol-level recommendations sometimes different. That difference is not regulatory drift. It is operator-practice drift, and it matters more than the database lookup suggests.

Sofwave's U.S. indication expansion and the eyebrow lift clearance

Sofwave is the synchronous ultrasound parallel beam (SUPERB) device that received its initial U.S. FDA 510(k) clearance in 2019 for improvement of facial fine lines and wrinkles, with subsequent clearances expanding into lifting of lax submental and neck tissue and, in the more recent 2024-2025 window, an indication for short-term improvement of eyebrow appearance and lifting of lax submental and neck tissue in a refined cleared-indication statement. The eyebrow indication clearance is the headline story of the Sofwave U.S. file in this window, and it has reshaped how American dermatology offices position SUPERB next to Ulthera in consultation.

The practical patient takeaway from the eyebrow clearance is that U.S. providers can now market Sofwave for a brow indication without the off-label conversation that previously framed any brow-zone Sofwave session. That is meaningful for U.S. patients shopping the U.S. market. For patients who book in Korea, the relevance is more indirect: the broader Sofwave indication set in the U.S. has put pricing pressure on Sofwave in Seoul, and several Gangnam coordinators I spoke with this trip described the Sofwave-Ulthera price spread as narrowing in 2025-2026 partly because of the U.S. competitive picture.

A conflict-of-interest note that I would want any reader to weigh. Sofwave Medical has historically sponsored or co-authored a meaningful share of the comparative MFU/SUPERB literature, which is something I keep in mind when I read the post-clearance outcome papers. Studies suggest that the SUPERB mechanism is well-supported as a category; the head-to-head comparisons between Sofwave and Ulthera in independent settings remain limited, and the FDA clearance letter does not resolve that gap. May help is the right framing for any patient who wants the cleanest read.

Pediatric language, contraindications, and what changed

MFU lifting platforms are not cleared for pediatric populations in the United States, and the cleared-indication language across both Ulthera and Sofwave has remained adult-only throughout the 2024-2026 window. What did change in this period is how the manufacturer-supplied contraindication and labeling guidance is structured. Pregnancy and active dermal-zone infection have always been listed contraindications. The 2024-2025 update cycle added clearer language around recent neuromodulator placement, recent dermal filler placement in the treatment zone, and active autoimmune flare on the skin in the treatment zone — all of which had previously been operator-judgment territory and are now closer to being labeled.

For patients, the meaningful effect of the contraindication language tightening is that U.S. providers are increasingly asking standardized intake questions before booking an MFU session, which mirrors the intake form most reputable Gangnam clinics have already been using. If you booked an Ulthera or Sofwave session in 2022 and the intake felt thinner than what you experienced in 2025, the difference is the post-market surveillance and labeling cycle catching up with operator practice rather than a new clinical concern emerging mid-cycle.

A second labeling point worth noting. The post-procedure expectation language — "results may take three to six months to fully appear, with continued tightening over a longer horizon" — has been formalized in U.S. consumer materials in this window. That language was previously implied and is now explicit, which I read as a positive development. Patients report that managed expectations are the biggest single driver of post-procedure satisfaction, and aligning U.S. consumer-facing materials with the realistic timeline reduces the disappointment-versus-result gap that occasionally shows up in U.S. review channels.

Ulthera vs Sofwave 510(k) status, side by side, 2026

For patients trying to read the FDA picture quickly without combing the database, the categorical comparison below is what I keep on the inside cover of my notes. Read it as descriptive — a snapshot of where each platform sits in the U.S. cleared-indication picture as of early 2026, not a clinical recommendation.

What the U.S. clearance picture means for patients comparing Korea

Here is the question I get most often from American friends who are weighing a U.S. session against a Korean trip: does the FDA picture make Korea less attractive, more attractive, or about the same? My honest read, after watching this for several years and running the numbers each trip, is that the FDA picture is a stabilizer rather than a deciding factor. The cleared indications in the U.S. are largely the same as the indications a Korean provider will discuss in consultation, the platforms are the same platforms (Ulthera, Ultherapy Prime, Sofwave all hold dual U.S. and Korean clearances), and the post-market surveillance reporting flows in both directions across the two regulators.

What the U.S. picture does not capture is the operator-volume and price-step difference that drives most of my Korea-versus-U.S. comparison. A U.S. provider running twenty Ulthera sessions a year on a familiar device will produce a reliable result, often at a price step that is meaningfully higher than the Gangnam equivalent. A Gangnam provider running fifteen Ulthera sessions a week will have a different muscle-memory baseline at a different price point. Studies suggest the platform mechanism is well-supported on both sides of the Pacific. The provider's hand on the platform is what carries the result.

A practical conclusion. If you are shopping the U.S. market, the 2024-2026 Sofwave eyebrow clearance and the Ulthera Prime stabilization are both reasons to feel reassured about the U.S. options on the table. If you are comparing the U.S. and Korean markets, the FDA picture confirms that the regulatory floor is comparable, and the decision tilts on operator volume, language support, recovery logistics, and the price step you are willing to pay. None of that is a reason to fly to Seoul for a session you could get reliably at home. It is a reason to make the comparison on operator and trip economics, not on regulatory adequacy.

Frequently asked questions

Is FDA 510(k) clearance the same as clinical superiority?

No. A 510(k) clearance is a regulatory finding of safety and substantial equivalence to a legally marketed predicate device for a specified indication. It is not a comparative-superiority statement. The published outcome data, the operator's case volume, and the post-market surveillance record do additional work that the clearance letter does not. Patients should treat 510(k) clearance as a permission floor and weigh independent literature and operator experience above it.

What changed for Sofwave in the 2024-2026 FDA window?

The headline change was the eyebrow indication clearance, which formalized the brow-zone application of the SUPERB platform and reshaped how U.S. dermatology offices position Sofwave next to Ulthera. The cleared indications also include lifting of lax submental and neck tissue and improvement of facial fine lines and wrinkles. The eyebrow clearance closed the off-label conversation that previously framed any brow-zone Sofwave session in U.S. practice.

Has Ultherapy Prime been FDA-cleared for the U.S. market?

Yes. Ulthera, Inc. received FDA 510(k) clearance for the Prime hardware platform in early 2023, with the same cleared indications as the original Ultherapy device — brow lift, lifting of lax submental and neck tissue, and improvement of fine lines and wrinkles on the décolletage. The Korean MFDS clearance followed later in 2023, with commercial sales into Korean clinics beginning in earnest in early 2024.

Are MFU devices FDA-cleared for pediatric patients in the United States?

No. Both Ulthera and Sofwave hold adult-only cleared indications, and the 2024-2026 update cycle did not change that scope. MFU lifting platforms are not cleared for use in pediatric populations in the United States, and reputable U.S. providers will not perform an MFU session on a patient under the age of consent for cosmetic procedures. The labeling has been consistent on this point throughout the platforms' clearance histories.

What did the contraindication language tightening in 2024-2025 actually cover?

Pregnancy and active dermal-zone infection have always been listed contraindications. The 2024-2025 cycle added clearer manufacturer-supplied language around recent neuromodulator placement, recent dermal filler placement in the treatment zone, and active autoimmune flare on the skin in the treatment zone. All three had previously been operator-judgment territory. The labeling change reflects post-market surveillance catching up with operator practice rather than a new clinical concern emerging mid-cycle.

Does the FDA picture make Korea more or less attractive for an MFU session?

Neither, in my reading. The cleared indications and platforms are largely the same on both sides of the Pacific, and the regulatory floor is comparable. The U.S.-versus-Korea decision tilts on operator volume, language support, recovery logistics, and the price step a patient is willing to pay — not on regulatory adequacy. The 2024-2026 FDA window is best read as a stabilizer of the U.S. options rather than a reason to choose one country over the other.